# BridgeBio Pharma, Inc.: overview

BBIO · Nasdaq · CIK 1743881 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bbio.md) · [Financials](/companies/bbio/financials.md) · [Filings](/companies/bbio/filings.md) · [Insiders](/companies/bbio/insiders.md)

Latest reported revenue: [$353.2m](/filings/0001743881-26-000034.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001743881-26-000034).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5.9 d](/filings/0001743881-26-000009.md) | [117](/filings/0001743881-26-000019.md) | [111](/filings/0001743881-26-000027.md) | [121](/filings/0001743881-26-000034.md) | [154 d](/filings/0001743881-26-000009.md) | [195](/filings/0001743881-26-000019.md) | [244](/filings/0001743881-26-000027.md) | [353](/filings/0001743881-26-000034.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(3842.7%) d](/filings/0001743881-26-000009.md) | [(89.5%)](/filings/0001743881-26-000019.md) | [(121.4%)](/filings/0001743881-26-000027.md) | [(120.3%)](/filings/0001743881-26-000034.md) | [(90.5%) d](/filings/0001743881-26-000009.md) | [(54.5%)](/filings/0001743881-26-000019.md) | [(43.9%)](/filings/0001743881-26-000027.md) | [(3.3%)](/filings/0001743881-26-000034.md) |
| Net margin | % | [(4545.9%) d](/filings/0001743881-26-000009.md) | [(145.4%)](/filings/0001743881-26-000019.md) | [(166.2%)](/filings/0001743881-26-000027.md) | [(151.4%)](/filings/0001743881-26-000034.md) | [(130.3%) d](/filings/0001743881-26-000009.md) | [(85.6%)](/filings/0001743881-26-000019.md) | [(64.0%)](/filings/0001743881-26-000027.md) | [(16.1%)](/filings/0001743881-26-000034.md) |
| Diluted EPS | $ per share | not reported | [(0.88)](/filings/0001743881-26-000019.md) | [(0.95)](/filings/0001743881-26-000027.md) | [(0.95)](/filings/0001743881-26-000034.md) | not reported | [(0.84)](/filings/0001743881-26-000019.md) | [(0.78)](/filings/0001743881-26-000027.md) | [(0.42)](/filings/0001743881-26-000034.md) |
| Free cash flow | $m | [(195) d](/filings/0001743881-26-000009.md) | [(199)](/filings/0001743881-26-000019.md) | [(81.3) d](/filings/0001743881-26-000027.md) | [(110) d](/filings/0001743881-26-000034.md) | [(56.5) d](/filings/0001743881-26-000009.md) | [(197)](/filings/0001743881-26-000019.md) | [(71.5) d](/filings/0001743881-26-000027.md) | [(44.5) d](/filings/0001743881-26-000034.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [69.7](/filings/0000950170-24-018811.md) | [77.6](/filings/0000950170-25-024119.md) | [9.3](/filings/0001743881-26-000009.md) | [222](/filings/0001743881-26-000009.md) | [502](/filings/0001743881-26-000009.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(827.1%)](/filings/0000950170-24-018811.md) | [(659.6%)](/filings/0000950170-25-024119.md) | [(6528.8%)](/filings/0001743881-26-000009.md) | [(267.2%)](/filings/0001743881-26-000009.md) | [(104.2%)](/filings/0001743881-26-000009.md) |
| Net margin | % | [(841.2%)](/filings/0000950170-24-018811.md) | [(624.2%)](/filings/0000950170-25-024119.md) | [(7021.9%)](/filings/0001743881-26-000009.md) | [(244.9%)](/filings/0001743881-26-000009.md) | [(146.0%)](/filings/0001743881-26-000009.md) |
| Diluted EPS | $ per share | [(3.90)](/filings/0000950170-24-018811.md) | [(3.26)](/filings/0000950170-25-024119.md) | [(3.95)](/filings/0001743881-26-000009.md) | [(2.88)](/filings/0001743881-26-000009.md) | [(3.78)](/filings/0001743881-26-000009.md) |
| Free cash flow | $m | [(511)](/filings/0000950170-24-018811.md) | [(424)](/filings/0000950170-25-024119.md) | [(529)](/filings/0001743881-26-000009.md) | [(522)](/filings/0001743881-26-000009.md) | [(447)](/filings/0001743881-26-000009.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bbio/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2025-05-12 | [KKR Genetic Disorder L.P.](/insiders/1780408.md) | 10% owner | Sale (S) | 6,000,000 | $34.20 | $205.2m | [Form 4](/filings/0001140361-25-019003.md) |
| 2025-03-05 | [KKR Genetic Disorder L.P.](/insiders/1780408.md) | 10% owner | Sale (S) | 6,000,000 | $32.96 | $197.8m | [Form 4](/filings/0001140361-25-007699.md) |
| 2024-09-13 | [KKR Genetic Disorder L.P.](/insiders/1780408.md) | 10% owner | Sale (S) | 5,800,000 | $25.75 | $149.3m | [Form 4](/filings/0001140361-24-041329.md) |
| 2021-02-17 | [KKR Genetic Disorder L.P.](/insiders/1780408.md) | 10% owner | Sale (S) | 3,450,000 | $60.4688 | $208.6m | [Form 4](/filings/0001140361-21-005267.md) |
| 2020-05-28 | [KKR Genetic Disorder L.P.](/insiders/1780408.md) | 10% owner | Sale (S) | 2,389,690 | $33.39 | $79.8m | [Form 4](/filings/0001140361-20-012852.md) |
| 2019-07-01 | [KKR Genetic Disorder L.P.](/insiders/1780408.md) | 10% owner | Purchase (P) | 2,647,100 | $17.00 | $45.0m | [Form 4](/filings/0000899243-19-019173.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $1.05bn | 14,110,278 |  | Not compared |
| [Kohlberg Kravis Roberts & Co. L.P.](/funds/1399770.md) | 2026-06-30 | $987.7m | 13,260,971 |  | Unchanged |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $978.6m | 13,179,013 |  | Not compared |
| [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $800.1m | 10,743,063 |  | Added +1,377,600 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $766.2m | 10,287,156 |  | Reduced −3,920,601 |
| [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $741.0m | 9,949,219 |  | Reduced −1,893,215 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $588.3m | 7,898,973 |  | Added +139,478 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $570.3m | 7,656,722 |  | Reduced −423,851 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $395.4m | 5,308,924 |  | Added +2,824,971 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $351.7m | 4,722,185 |  | Added +1,601,554 |

## Recent filings

[All 822 filings](/companies/bbio/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:52 ET | [10-Q](/filings/0001743881-26-000034.md) | Quarterly report, period 2026-09-30 | 0001743881-26-000034 |
| 2026-10-29 | 16:03 ET | [8-K](/filings/0001743881-26-000033.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001743881-26-000033 |
| 2026-10-13 | 06:01 ET | [8-K](/filings/0001140361-26-039334.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-039334 |
| 2026-08-31 | 15:54 ET | [8-K](/filings/0001140361-26-035055.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-035055 |
| 2026-08-17 | 17:30 ET | [SCHEDULE 13D/A](/filings/0001140361-26-033404.md) | Ownership report, active investor, amended | 0001140361-26-033404 |
| 2026-08-17 | 09:05 ET | [8-K](/filings/0001140361-26-033282.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-033282 |
| 2026-08-10 | 16:31 ET | [10-Q](/filings/0001743881-26-000027.md) | Quarterly report, period 2026-06-30 | 0001743881-26-000027 |
| 2026-08-10 | 16:03 ET | [8-K](/filings/0001743881-26-000026.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001743881-26-000026 |
| 2026-07-22 | 16:34 ET | [8-K](/filings/0001140361-26-029291.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-029291 |
| 2026-07-10 | 19:03 ET | [SCHEDULE 13D/A](/filings/0000905148-26-003237.md) | Ownership report, active investor, amended | 0000905148-26-003237 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001743881-26-000009.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/bd89987b-3534-4007-826b-ab2dcbfca714)

## About the filer

- CIK: 1743881
- Tickers: BBIO
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 19:20 ET. No prices; not investment advice.